Establish Bone Repair Biomaterials Database via FDA Scraping & Clinical Trial Aggregation
- Organization
- NSF SBIR Phase II commercialization plan requirement (mandates competitive analysis without providing tools)
- Sector
- SBIR-funded biomaterial companies needing comparative efficacy data for Phase II applications
- Location
- Location unspecified
Source Reference
Executive Context
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Catalyst / Timing
NSF requires a commercialization plan for Phase II proposals but provides no standardized database for competitive analysis. CYTROGEN and hundreds of other SBIR biomaterial companies must individually research FDA submissions, clinical trials, and competitive products—a repetitive, inefficient process ripe for centralization.
Projected Yield
$299-999/month subscriptions × 50 companies = $15k-50k/month recurring revenue
Structural Friction
• Vulnerability: NSF requires a commercialization plan for Phase II proposals but provides no standardized database for competitive analysis. CYTROGEN and hundreds of other SBIR biomaterial companies must individually research FDA submissions, clinical trials, and competitive products—a repetitive, inefficient process ripe for centralization. • Capital yield: $299-999/month subscriptions × 50 companies = $15k-50k/month recurring revenue • Resource capture: Proprietary dataset of FDA clearances, clinical outcomes, and competitive positioning • Influence capture: Gatekeeper position for SBIR Phase II competitive analysis • Sovereignty yield: Definitive bone repair biomaterials database establishing market authority • Required vectors: Vector: Data Engineering & Web Scraping, Vector: Regulatory Intelligence (FDA), Vector: SaaS Product Development
Required Capabilities
Vector: Data Engineering & Web Scraping
Primary executor: Phase 1: Database Architecture & Source Mapping: Map all public data sources: (1) FDA 510(k) database via API, (2) Clini
Vector: Regulatory Intelligence (FDA)
Supporting vector for: Establish Bone Repair Biomaterials Database via FDA Scraping & Clinical Trial Ag
Vector: SaaS Product Development
Supporting vector for: Establish Bone Repair Biomaterials Database via FDA Scraping & Clinical Trial Ag
Execution Protocol
Execution Protocol Locked
A one-time payment of $649 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.